Novavax Inc (NVAX.O)

NVAX.O on Nasdaq

11.62USD
28 Aug 2015
Change (% chg)

-- (+0.00%)
Prev Close
$11.62
Open
$11.36
Day's High
$11.70
Day's Low
$11.28
Volume
3,788,309
Avg. Vol
4,642,690
52-wk High
$15.01
52-wk Low
$3.92

NVAX.O

Chart for NVAX.O

About

Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The... (more)

Overall

Beta: 1.05
Market Cap(Mil.): $3,133.22
Shares Outstanding(Mil.): 269.64
Dividend: --
Yield (%): --

Financials

  NVAX.O Industry Sector
P/E (TTM): -- 70.22 36.13
EPS (TTM): -0.39 -- --
ROI: -27.82 0.47 14.83
ROE: -28.77 0.34 15.69
Search Stocks

Novavax's vaccine first to protect against common respiratory virus

- A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children.

10 Aug 2015

REFILE-Novavax's vaccine first to protect against common respiratory virus

Aug 10 - A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children.

10 Aug 2015

BRIEF-Novavax Inc says positive top-line data from RSV F-protein vaccine clinical trial in older adults

* Positive top-line data from phase 2 RSV F-protein vaccine clinical trial in older adults

10 Aug 2015

Novavax hopes to crack elusive vaccine for common respiratory virus

- A Maryland-based biotech company believes it can solve a riddle that has baffled Big Pharma for decades: how to protect against a virus that infects almost every American child.

10 Aug 2015

Novavax's Ebola vaccine shows promise in early-stage trial

- Novavax Inc said its experimental Ebola vaccine induced a substantial immune response to the deadly infection in an early-stage trial involving 230 healthy adults.

21 Jul 2015

UPDATE 1-Novavax's Ebola vaccine shows promise in early-stage trial

* Stock hits more than 13-year high in morning trade (Adds details, executive comments, shares)

21 Jul 2015

BRIEF-Novavax Inc says positive top-line data From Phase 1 Ebola vaccine trial

* Positive top-line data from phase 1 trial of ebola virus glycoprotein recombinant nanoparticle vaccine candidate adjuvanted with matrix-m

21 Jul 2015

Novavax extends gains, hits highest since 2002

NEW YORK, June 23 - **Shares of Novavax extend gains in late afternoon trading on Tuesday; last up 11.7 percent at $11.12 after hitting its highest level since April 2002.

23 Jun 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF94.20 -0.15
Merck & Co., Inc. (MRK.N) $55.37 +0.42
Sanofi SA (SASY.PA) €88.44 -0.12
GlaxoSmithKline plc (GSK.L) 1,340.50p +9.50
AstraZeneca plc (AZN.L) 4,120.00p +36.00

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Reuters Investment Profile
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks